EP Patent

EP0952148B1 — Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives

Assigned to Pfizer Products Inc · Expires 2004-05-12 · 22y expired

What this patent protects

A compound of the formula <CHEM> wherein Y is as defined above, useful in the treatment of arthritis or cancer and other diseases involving selective inhibition of matrix metalloproteinase-13.

USPTO Abstract

A compound of the formula <CHEM> wherein Y is as defined above, useful in the treatment of arthritis or cancer and other diseases involving selective inhibition of matrix metalloproteinase-13.

Drugs covered by this patent

Patent Metadata

Patent number
EP0952148B1
Jurisdiction
EP
Classification
—
Expires
2004-05-12
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Products Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.